X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
5-fluorouracil (1722) 1722
humans (1502) 1502
oncology (1408) 1408
chemotherapy (1178) 1178
female (1094) 1094
male (1061) 1061
middle aged (1032) 1032
aged (990) 990
index medicus (941) 941
cisplatin (925) 925
antineoplastic combined chemotherapy protocols - therapeutic use (853) 853
adult (818) 818
cancer (809) 809
fluorouracil (627) 627
treatment outcome (599) 599
fluorouracil - administration & dosage (568) 568
cisplatin - administration & dosage (493) 493
antineoplastic combined chemotherapy protocols - adverse effects (463) 463
stomach neoplasms - drug therapy (451) 451
carcinoma (360) 360
gastric cancer (312) 312
trial (310) 310
care and treatment (299) 299
pharmacology & pharmacy (299) 299
metastasis (279) 279
disease-free survival (276) 276
oxaliplatin (272) 272
docetaxel (270) 270
stomach neoplasms - pathology (270) 270
research (268) 268
therapy (266) 266
survival rate (261) 261
aged, 80 and over (260) 260
survival analysis (255) 255
adenocarcinoma - drug therapy (254) 254
adenocarcinoma (250) 250
survival (250) 250
capecitabine (248) 248
drug administration schedule (247) 247
s-1 (247) 247
cancer therapies (243) 243
deoxycytidine - analogs & derivatives (241) 241
antineoplastic combined chemotherapy protocols - administration & dosage (235) 235
radiotherapy (234) 234
stomach cancer (234) 234
leucovorin (232) 232
drug combinations (228) 228
phase-ii (227) 227
combination (225) 225
surgery (223) 223
fluorouracil - adverse effects (220) 220
neoplasm staging (220) 220
prognosis (211) 211
tegafur - administration & dosage (209) 209
gemcitabine (205) 205
tumors (205) 205
phase-ii trial (203) 203
doxorubicin (196) 196
toxicity (196) 196
paclitaxel (190) 190
irinotecan (186) 186
deoxycytidine - administration & dosage (185) 185
retrospective studies (182) 182
combined modality therapy (177) 177
medicine & public health (177) 177
plus cisplatin (177) 177
leucovorin - administration & dosage (175) 175
fluorouracil - therapeutic use (173) 173
folinic acid (169) 169
carcinoma, squamous cell - drug therapy (165) 165
oxonic acid - administration & dosage (165) 165
chemoradiotherapy (163) 163
squamous-cell carcinoma (162) 162
clinical trials (161) 161
cancer research (160) 160
patients (159) 159
combination chemotherapy (158) 158
cisplatin - adverse effects (155) 155
colorectal cancer (154) 154
drug therapy (151) 151
health aspects (150) 150
taxoids - administration & dosage (150) 150
esophageal cancer (148) 148
methotrexate (147) 147
antineoplastic agents - therapeutic use (146) 146
supportive care (145) 145
neoplasm metastasis (142) 142
animals (140) 140
infusions, intravenous (136) 136
organoplatinum compounds - administration & dosage (135) 135
antineoplastic agents (132) 132
stomach neoplasms - mortality (132) 132
apoptosis (131) 131
randomized-trial (131) 131
esophageal neoplasms - drug therapy (130) 130
pancreatic cancer (130) 130
gastroenterology & hepatology (129) 129
dose-response relationship, drug (128) 128
antimitotic agents (126) 126
chemotherapy, adjuvant (126) 126
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1927) 1927
French (6) 6
German (6) 6
Japanese (5) 5
Italian (1) 1
Korean (1) 1
Polish (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2008, Volume 9, Issue 3, pp. 215 - 221
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2009, Volume 10, Issue 11, pp. 1063 - 1069
Summary Background The best chemotherapy regimen for metastatic gastric cancer is uncertain, but promising findings have been reported with irinotecan plus... 
Hematology, Oncology and Palliative Medicine | SUPPORTIVE CARE | 5-FLUOROURACIL | ONCOLOGY | HIGH-DOSE METHOTREXATE | DOXORUBICIN | ADVANCED ESOPHAGOGASTRIC CANCER | COOPERATIVE GROUP | EUROPEAN-ORGANIZATION | 1ST-LINE THERAPY | III TRIAL | CHEMOTHERAPY | Japan - epidemiology | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Stomach Neoplasms - secondary | Cisplatin - administration & dosage | Young Adult | Fluorouracil - therapeutic use | Fluorouracil - adverse effects | Time Factors | Adult | Camptothecin - administration & dosage | Female | Camptothecin - analogs & derivatives | Drug Administration Schedule | Risk Assessment | Administration, Oral | Tegafur - adverse effects | Tegafur - therapeutic use | Proportional Hazards Models | Treatment Outcome | Stomach Neoplasms - drug therapy | Adenocarcinoma - drug therapy | Adenocarcinoma - secondary | Oxonic Acid - adverse effects | Disease-Free Survival | Antimetabolites, Antineoplastic - therapeutic use | Oxonic Acid - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Antimetabolites, Antineoplastic - adverse effects | Aged | Infusions, Intravenous | Stomach Neoplasms - mortality | Drug Combinations | Adenocarcinoma - mortality | Chemotherapy | Oncology, Experimental | Information services | Research | Metastasis | Stomach cancer | Information services industry | Cancer | Fluorouracil | Index Medicus
Journal Article
Journal Article
British Journal of Cancer, ISSN 0007-0920, 10/2013, Volume 109, Issue 8, pp. 2079 - 2086
Background: This study aimed to determine whether combination S-1 plus cisplatin (CDDP) therapy, the most widely used therapy for Japanese patients with... 
advanced gastric cancer | TSU-68 | S-1 plus cisplatin therapy | TRIAL | AGENT | 5-FLUOROURACIL | CISPLATIN | ONCOLOGY | TEGAFUR | MITOMYCIN | COMBINATION | CHEMOTHERAPY
Journal Article
Journal Article
Cancer Science, ISSN 1347-9032, 09/2014, Volume 105, Issue 9, pp. 1189 - 1195
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2014, Volume 50, Issue 8, pp. 1437 - 1445
Journal Article
Japanese Journal of Clinical Oncology, ISSN 0368-2811, 08/2017, Volume 47, Issue 8, pp. 683 - 689
Journal Article
Gastric Cancer, ISSN 1436-3291, 1/2016, Volume 19, Issue 1, pp. 234 - 244
Journal Article
Journal Article